Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics

被引:59
作者
Platt, R
Davis, R
Finkelstein, J
Go, AS
Gurwitz, JH
Roblin, D
Soumerai, S
Ross-Degnan, D
Andrade, S
Goodman, MJ
Martinson, B
Raebel, MA
Smith, D
Ulcickas-Yood, M
Chan, KA
机构
[1] Harvard Med Sch, Boston, MA USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA
[5] Kaiser Permanente No Calif, Oakland, CA USA
[6] Fallon Healthcare Syst, Worcester, MA USA
[7] Kaiser Permanente Georgia, Atlanta, GA USA
[8] HealthPartners, Minneapolis, MN USA
[9] Kaiser Permanente Colorado, Denver, CO USA
[10] Kaiser Permanente NW, Portland, OR USA
[11] Henry Ford Hlth Syst, Detroit, MI USA
[12] Harvard Sch Publ Hlth, Boston, MA USA
关键词
pharmacoepidemiology; health services research; record linkage; automated database; health maintenance organizations;
D O I
10.1002/pds.607
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Research and education programs in therapeutics that combine the data, organizational capabilities, and expertise of several managed care organizations working in concert can serve an important role when a single organization is not large enough to address a question of interest, when diversity in populations or delivery systems is required, and when it is necessary to establish consistency of results in different settings. Nine members of the HMO Research Network, a consortium of health maintenance organizations (HMOs) that perform public domain research, have formed a Center for Education and Research on Therapeutics (CERT), sponsored by the Agency for Healthcare Research and Quality, to conduct multicenter research in therapeutics. The CERT uses a distributed organizational model with shared leadership, in which: data reside at the originating organization until they are needed to support a specific study. Extraction of data from the host computer systems, and some manipulation of data, is typically accomplished through computer programs that are developed centrally, then modified for use at each site. For complex studies, pooled analysis files are created by a coordinating center, and then analysed by investigators throughout the HMOs. It is also possible to contact HMO members when necessary. This multicenter environment has several benefits, addressing: (1) a wide array of questions about the safety and effectiveness of therapeutics, (2) the impact of efforts to change clinicians' and patients' behavior, and (3) pharmacoeconomic and pharmacogenetic questions. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 4 条
[1]   Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J].
Chan, KA ;
Andrade, SE ;
Boles, M ;
Buist, DSM ;
Chase, GA ;
Donahue, JG ;
Goodman, MJ ;
Gurwitz, JH ;
LaCroix, AZ ;
Platt, R .
LANCET, 2000, 355 (9222) :2185-2188
[2]  
Donahue James G., 2000, Pharmacoepidemiology and Drug Safety, V9, pS112
[3]   Contraindicated use of cisapride - Impact of food and drug administration regulatory action [J].
Smalley, W ;
Shatin, D ;
Wysowski, DK ;
Gurwitz, J ;
Andrade, SE ;
Goodman, M ;
Chan, KA ;
Platt, R ;
Schech, SD ;
Ray, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (23) :3036-3039
[4]   A CHRONIC DISEASE SCORE FROM AUTOMATED PHARMACY DATA [J].
VONKORFF, M ;
WAGNER, EH ;
SAUNDERS, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (02) :197-203